CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

This is due to the risks for serious adverse outcomes resulting from sedation, dissociation, respiratory depression, abuse, ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

The approval makes the treatment the first and only monotherapy for adults living with major depressive ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...